Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Angelica PaceFabio ScirocchiChiara NapoletanoIlaria Grazia ZizzariAgnese PoFrancesca MegiorniAngela AsquinoPaola PontecorviHassan RahimiCinzia MarcheseElisabetta FerrettiMarianna NutiAurelia RughettiPublished in: Journal of translational medicine (2023)
These results contribute to clarifying the biological effects and molecular mechanisms mediated by the anti-FGFR TKI pemigatinib in distinct tumor settings and support its exploitation for combined therapies.